The Drug Debate: Data Exclusivity is the New Way to Delay Generics

15 Pages Posted: 26 Jun 2018 Last revised: 27 Sep 2018

See all articles by Srividhya Ragavan

Srividhya Ragavan

Texas A&M University School of Law

Date Written: June 12, 2018

Abstract

The article discusses the protection regime for clinical trial data internationally and outlines the applicable protection regime. In doing so, this article outlines how the data exclusivity regime can operate in parallel with the patent regime to add a layer of protection for the data. Such protection operates at a regulatory level to delay the entry of generic medications. Internationally, the data exclusivity regime, which has become an important contemporary tool in trade negotiations with poorer nations, works to detrimentally affect access to medication.

Suggested Citation

Ragavan, Srividhya, The Drug Debate: Data Exclusivity is the New Way to Delay Generics (June 12, 2018). Connecticut Law Review Online, Vol. 50, No. 2, 2018, Available at SSRN: https://ssrn.com/abstract=3194772

Srividhya Ragavan (Contact Author)

Texas A&M University School of Law ( email )

1515 Commerce Street
Fort Worth, TX 76102
United States

Here is the Coronavirus
related research on SSRN

Paper statistics

Downloads
46
Abstract Views
569
PlumX Metrics